UroGen Pharma Ltd. (NASDAQ:URGN) Insider Mark Schoenberg Sells 4,551 Shares

UroGen Pharma Ltd. (NASDAQ:URGN) insider Mark Schoenberg sold 4,551 shares of the business’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $50,698.14. Following the completion of the sale, the insider now owns 145,666 shares in the company, valued at $1,622,719.24. This represents a 3.03 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

UroGen Pharma Stock Performance

NASDAQ:URGN traded up $0.14 during midday trading on Tuesday, hitting $11.35. The company’s stock had a trading volume of 106,431 shares, compared to its average volume of 348,812. UroGen Pharma Ltd. has a fifty-two week low of $9.78 and a fifty-two week high of $20.70. The firm’s 50 day moving average is $11.12 and its 200-day moving average is $12.64. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. The firm has a market cap of $266.09 million, a P/E ratio of -3.61 and a beta of 1.08.

UroGen Pharma (NASDAQ:URGN) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.55) EPS for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.29. The firm had revenue of $25.20 million for the quarter, compared to analyst estimates of $24.22 million. During the same period in the previous year, the business earned ($0.68) EPS. Equities analysts anticipate that UroGen Pharma Ltd. will post -3.12 earnings per share for the current fiscal year.

Institutional Investors Weigh In On UroGen Pharma

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Rhumbline Advisers grew its stake in shares of UroGen Pharma by 2.8% during the 4th quarter. Rhumbline Advisers now owns 51,270 shares of the company’s stock worth $546,000 after purchasing an additional 1,402 shares during the period. SG Americas Securities LLC grew its stake in shares of UroGen Pharma by 44.1% during the 4th quarter. SG Americas Securities LLC now owns 20,269 shares of the company’s stock worth $216,000 after purchasing an additional 6,207 shares during the period. JPMorgan Chase & Co. grew its stake in shares of UroGen Pharma by 263.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 68,062 shares of the company’s stock worth $864,000 after purchasing an additional 49,318 shares during the period. Tidal Investments LLC grew its stake in shares of UroGen Pharma by 19.1% during the 3rd quarter. Tidal Investments LLC now owns 37,595 shares of the company’s stock worth $477,000 after purchasing an additional 6,030 shares during the period. Finally, Barclays PLC lifted its position in shares of UroGen Pharma by 409.3% during the 3rd quarter. Barclays PLC now owns 59,778 shares of the company’s stock valued at $759,000 after buying an additional 48,040 shares in the last quarter. Institutional investors and hedge funds own 91.29% of the company’s stock.

Analysts Set New Price Targets

URGN has been the topic of a number of research analyst reports. D. Boral Capital restated a “buy” rating and issued a $25.00 price target on shares of UroGen Pharma in a report on Thursday, January 23rd. Oppenheimer reissued an “outperform” rating and set a $40.00 price target on shares of UroGen Pharma in a research report on Wednesday, October 16th. HC Wainwright reissued a “buy” rating and set a $60.00 price target on shares of UroGen Pharma in a research report on Tuesday, October 15th. Finally, EF Hutton Acquisition Co. I raised shares of UroGen Pharma to a “strong-buy” rating in a research report on Monday, October 14th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $43.70.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.